OpenLB
Open Library of Bioscience

Schizophrenia in a genomic era: a review from the pathogenesis, genetic and environmental etiology to diagnosis and treatment insights.

Abstract

References

1. Abdolmaleky HM, Cheng KH, Russo A, Smith CL, Faraone SV, Wilcox M, et al. Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report. Am J Med Genet B Neuropsychiatr Genet. 2005; 134B:60–66
2. Abdolmaleky HM, Faraone SV, Glatt SJ, Tsuang MT. Meta-analysis of association between the T102C polymorphism of the 5HT2A receptor gene and schizophrenia. Schizophr Res. 2004; 67:53–62
3. Alloza C, Cox SR, Blesa Cábez M, Redmond P, Whalley HC, Ritchie SJ, et al. Polygenic risk score for schizophrenia and structural brain connectivity in older age: a longitudinal connectome and tractography study. Neuroimage. 2018; 183:884–896
4. Altamura AC, Buoli M, Pozzoli S. Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: comparison with schizophrenia. Psychiatry Clin Neurosci. 2014; 68:21–36
5. American-Psychiatric-Association. Diagnostic and Statistical Manual of Mental Disorders. 2013. 5th ed, Washington, DC: American Psychiatric Publication
6. Aricioglu F, Ozkartal CS, Unal G, Dursun S, Cetin M, Müller N. Neuroinflammation in schizophrenia: a critical review and the future. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology. 2016; 26:429–437
7. Arinami T, Itokawa M, Enguchi H, Tagaya H, Yano S, Shimizu H, et al. Association of dopamine D2 receptor molecular variant with schizophrenia. Lancet. 1994; 343:703–704
8. Benzel I, Bansal A, Browning BL, Galwey NW, Maycox PR, McGinnis R, et al. Interactions among genes in the erbb-neuregulin signalling network are associated with increased susceptibility to schizophrenia. Behav Brain Funct. 2007; 3:31
9. Bettella F, Brown AA, Smeland OB, Wang Y, Witoelar A, Buil Demur AA, et al. Cross-tissue eqtl enrichment of associations in schizophrenia. Plos One. 2018; 13:e0202812
10. Birnbaum R, Weinberger DR. Genetic insights into the neurodevelopmental origins of schizophrenia. Nat Rev Neurosci. 2017; 18:727–740
11. Blasi G, Napolitano F, Ursini G, Taurisano P, Romano R, Caforio G, et al. DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia. Proc Natl Acad Sci U S A. 2011; 108:1158–1163
12. Bliksted V, Videbech P, Fagerlund B, Frith C. The effect of positive symptoms on social cognition in first-episode schizophrenia is modified by the presence of negative symptoms. Neuropsychology. 2017; 31:209–219
13. Brennand KJ, Simone A, Jou J, Gelboin-Burkhart C, Tran N, Sangar S, et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature. 2011; 473:221–225
14. Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry. 2010; 167:261–280
15. Brown AS, Susser ES. In utero infection and adult schizophrenia. Ment Retard Dev Disabil Res Rev. 2002; 8:51–57
16. Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Bernstein D, Yolken R H. Maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry. 2001; 58:1032–1037
17. Cai L, Huang T, Su J, Zhang X, Chen W, Zhang F, et al. Implications of newly identified brain eqtl genes and their interactors in schizophrenia. Mol Ther Nucleic Acids. 2018; 12:433–442
18. Cannon M, Jones PB, Murray RM. Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry. 2002; 159:1080–1092
19. Caspi A, Moffitt TE. Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat Rev Neurosci. 2006; 7:583–590
20. Chang X, Lima LA, Liu Y, Li J, Li Q, Sleiman PMA, Hakonarson H. Common and rare genetic risk factors converge in protein interaction networks underlying schizophrenia. Front Genet. 2018; 9:434
21. Chen X, Lee G, Maher BS, Fanous AH, Chen J, Zhao Z, et al.; GROUP investigators; International Schizophrenia Consortium. GWA study data mining and independent replication identify cardiomyopathy-associated 5 (CMYA5) as a risk gene for schizophrenia. Mol Psychiatry. 2011; 16:1117–1129
22. Chen X, Wang X, O’Neill AF, Walsh D, Kendler KS. Variants in the catechol-o-methyltransferase (COMT) gene are associated with schizophrenia in Irish high-density families. Mol Psychiatry. 2004; 9:962–967
23. Clarke M, Kelleher E. SU57. Obstetric complications and schizophrenia—systematic review and meta-analysis update. Schizophrenia Bulletin. 2017; 43Suppl 1S182
24. Clarke MC, Tanskanen A, Huttunen M, Whittaker JC, Cannon M. Evidence for an interaction between familial liability and prenatal exposure to infection in the causation of schizophrenia. Am J Psychiatry. 2009; 166:1025–1030
25. Dachew BA, Mamun A, Maravilla JC, Alati R. Association between hypertensive disorders of pregnancy and the development of offspring mental and behavioural problems: a systematic review and meta-analysis. Psychiatry Res. 2018; 260:458–467
26. Davies G, Welham J, Chant D, Torrey EF, McGrath J. A systematic review and meta-analysis of northern hemisphere season of birth studies in schizophrenia. Schizophr Bull. 2003; 29:587–593
27. de la Fontaine L, Schwarz MJ, Riedel M, Dehning S, Douhet A, Spellmann I, Gruber R. Investigating disease susceptibility and the negative correlation of schizophrenia and rheumatoid arthritis focusing on MIF and CD14 gene polymorphisms. Psychiatry Research. 2006; 144:39–47
28. Fatemi HS. Neuropsychiatric Disorders and Infection. 2005, London: CRC Press. https://doi.org/10.3109/9780203007648
29. Fatemi SH, Folsom TD, Rooney RJ, Mori S, Kornfield TE, Reutiman TJ, Patel DH. The viral theory of schizophrenia revisited: abnormal placental gene expression and structural changes with lack of evidence for H1N1 viral presence in placentae of infected mice or brains of exposed offspring. Neuropharmacology. 2012; 62:1290–1298
30. Feigenson KA, Kusnecov AW, Silverstein SM. Inflammation and the two-hit hypothesis of schizophrenia. Neurosci Biobehav Rev. 2014; 38:72–93
31. Gallego JA, Blanco EA, Husain-Krautter S, Madeline Fagen E, Moreno-Merino P, Del Ojo-Jiménez JA, et al. Cytokines in cerebrospinal fluid of patients with schizophrenia spectrum disorders: new data and an updated meta-analysis. Schizophr Res. 2018; 202:64–71
32. Gandal MJ, Zhang P, Hadjimichael E, Walker RL, Chen C, Liu S, Geschwind DH. Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. Science. 2018; 362:eaat8127
33. Gejman PV, Sanders AR, Kendler KS. Genetics of schizophrenia: new findings and challenges. Annu Rev Genomics Hum Genet. 2011; 12:121–144
34. Gilmore JH, Jarskog LF. Exposure to infection and brain development: cytokines in the pathogenesis of schizophrenia. Schizophr Res. 1997; 24:365–367
35. Gorwood P, Pouchot J, Vinceneux P, Puéchal X, Flipo RM, De Bandt M, Adès J; Club Rhumatisme et Inflammation. Rheumatoid arthritis and schizophrenia: a negative association at a dimensional level. Schizophr Res. 2004; 66:21–29
36. Gulsuner S, McClellan JM. Copy number variation in schizophrenia. Neuropsychopharmacology. 2015; 40:252–254
37. Häfner H, Maurer K, Löffler W, an der Heiden W, Stein A, Könnecke R, Hambrecht M. Onset and prodromal phase as determinants of the course. Search for the causes of schizophrenia. 1999Springer35–58
38. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry. 2005; 10:40–68; image 5
39. He H, Wu H, Yang L, Gao F, Fan Y, Feng J, Ma X. Associations between dopamine D2 receptor gene polymorphisms and schizophrenia risk: a PRISMA compliant meta-analysis. Neuropsychiatr Dis Treat. 2016; 12:3129–3144
40. Henriksen MG, Nordgaard J, Jansson LB. Genetics of schizophrenia: overview of methods, findings and limitations. Front Hum Neurosci. 2017; 11:322
41. Hilker R, Helenius D, Fagerlund B, Skytthe A, Christensen K, Werge TM, et al. Heritability of schizophrenia and schizophrenia spectrum based on the nationwide danish twin register. Biol Psychiatry. 2018; 83:492–498
42. Hoffmann A, Ziller M, Spengler D. Childhood-onset schizophrenia: insights from induced pluripotent stem cells. Int J Mol Sci. 2018; 19:E3829
43. Hong CJ, Yu YW, Lin CH, Cheng CY, Tsai SJ. Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia. Psychiatr Genet. 2001; 11:219–222
44. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III–the final common pathway. Schizophr Bull. 2009; 35:549–562
45. Hu W, MacDonald ML, Elswick DE, Sweet RA. The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies. Ann N Y Acad Sci. 2015; 1338:38–57
46. Ikeda M, Takahashi A, Kamatani Y, Momozawa Y, Saito T, Kondo K, et al. Genome-wide association study detected novel susceptibility genes for schizophrenia and shared trans-populations/diseases genetic effect. Schizophr Bull. 2019; 45:824–834
47. Inoubli O, Jemli A, Ben Fredj S, Mechri A, Gaha L, Bel Hadj Jrad B. Haplotypes of tnfα/β genes associated with sex-specific paranoid schizophrenic risk in Tunisian population. Dis Markers. 2018; 2018:3502564
48. Janecka M, Mill J, Basson MA, Goriely A, Spiers H, Reichenberg A, Fernandes C. Advanced paternal age effects in neurodevelopmental disorders-review of potential underlying mechanisms. Transl Psychiatry. 2017; 7:e1019
49. Jarskog LF, Miyamoto S, Lieberman JA. Schizophrenia: new pathological insights and therapies. Annu Rev Med. 2007; 58:49–61
50. Javitt DC, Spencer KM, Thaker GK, Winterer G, Hajós M. Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov. 2008; 7:68–83
51. Jones C, Cormac I, Silveira da Mota Neto JI, Campbell C. Cognitive behaviour therapy for schizophrenia. Cochrane Database Syst Rev. 2004. Art. No.: CD000524. doi: 10.1002/14651858.CD000524.pub2 [DOI: 10.1002/14651858.cd000524.pub2]
52. Kamiya A, Kubo K, Tomoda T, Takaki M, Youn R, Ozeki Y, et al. A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development. Nat Cell Biol. 2005; 7:1167–1178
53. Keller WR, Fischer BA, Carpenter WT Jr. Revisiting the diagnosis of schizophrenia: where have we been and where are we going?. CNS Neurosci Ther. 2011; 17:83–88
54. Khandaker GM, Zimbron J, Dalman C, Lewis G, Jones PB. Childhood infection and adult schizophrenia: a meta-analysis of population-based studies. Schizophr Res. 2012; 139:161–168
55. Kim YK, Jung HG, Myint AM, Kim H, Park SH. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord. 2007; 104:91–95
56. Kochunov P, Hong LE. Neurodevelopmental and neurodegenerative models of schizophrenia: white matter at the center stage. Schizophr Bull. 2014; 40:721–728
57. Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry. 2000; 157:683–694
58. Kushima I, Aleksic B, Nakatochi M, Shimamura T, Okada T, Uno Y, et al. Comparative analyses of copy-number variation in autism spectrum disorder and schizophrenia reveal etiological overlap and biological insights. Cell Rep. 2018; 24:2838–2856
59. Kyle UG, Pichard C. The Dutch famine of 1944-1945: a pathophysiological model of long-term consequences of wasting disease. Curr Opin Clin Nutr Metab Care. 2006; 9:388–394
60. Lewis DA, Gonzalez-Burgos G. Pathophysiologically based treatment interventions in schizophrenia. Nat Med. 2006; 12:1016–1022
61. Lewis DA, Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci. 2002; 25:409–432
62. Li Z, Chen J, Yu H, He L, Xu Y, Zhang D, et al. Genome-wide association analysis identifies 30 new susceptibility loci for schizophrenia. Nat Genet. 2017; 49:1576–1583
63. Lichtenstein P, Yip BH, Björk C, Pawitan Y, Cannon TD, Sullivan PF, Hultman CM. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet. 2009; 373:234–239
64. Liu J, Shi Y, Tang W, Guo T, Li D, Yang Y, et al. Positive association of the human GABA-A-receptor beta 2 subunit gene haplotype with schizophrenia in the Chinese Han population. Biochem Biophys Res Commun. 2005; 334:817–823
65. Liu Q, Du J, Fan J, Li W, Guo W, Feng H, Lin J. Generation and characterization of induced pluripotent stem cells from mononuclear cells in schizophrenic patients. Cell J. 2019; 21:161–168
66. Malavia TA, Chaparala S, Wood J, Chowdari K, Prasad KM, McClain L, et al. Generating testable hypotheses for schizophrenia and rheumatoid arthritis pathogenesis by integrating epidemiological, genomic, and protein interaction data. NPJ Schizophr. 2017; 3:11
67. Manolio TA, Rodriguez LL, Brooks L, Abecasis Gß, Ballinger D, Daly M, Gabriel S. New models of collaboration in genome-wide association studies: the Genetic Association Information Network. Nature genetics. 2007; 39:1045–1051
68. Marder SR, Galderisi S. The current conceptualization of negative symptoms in schizophrenia. World Psychiatry. 2017; 16:14–24
69. Marshall CR, Howrigan DP, Merico D, Thiruvahindrapuram B, Wu W, Greer DS, et al.; Psychosis Endophenotypes International Consortium; CNV and Schizophrenia Working Groups of the Psychiatric Genomics Consortium. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nat Genet. 2017; 49:27–35
70. Messias EL, Chen CY, Eaton WW. Epidemiology of schizophrenia: review of findings and myths. Psychiatr Clin North Am. 2007; 30:323–338
71. Millar JK, Pickard BS, Mackie S, James R, Christie S, Buchanan SR, et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate camp signaling. Science. 2005; 310:1187–1191
72. Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry. 2001; 6:293–301
73. Misiak B, Stanczykiewicz B, Kotowicz K, Rybakowski JK, Samochowiec J, Frydecka D. Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: A systematic review. Schizophr Res. 2018; 192:16–29
74. Modinos G, Iyegbe C, Prata D, Rivera M, Kempton MJ, Valmaggia LR, McGuire P. Molecular genetic gene-environment studies using candidate genes in schizophrenia: a systematic review. Schizophr Res. 2013; 150:356–365
75. Monji A, Kato T, Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci. 2009; 63:257–265
76. Müller N, Weidinger E, Leitner B, Schwarz M. The role of inflammation and the immune system in schizophrenia. The Neurobiology of Schizophrenia. 2016Elsevier179–193
77. Munafò MR, Thiselton DL, Clark TG, Flint J. Association of the NRG1 gene and schizophrenia: a meta-analysis. Mol Psychiatry. 2006; 11:539–546
78. Ng MY, Levinson DF, Faraone SV, Suarez BK, DeLisi LE, Arinami T, et al. Meta-analysis of 32 genome-wide linkage studies of schizophrenia. Mol Psychiatry. 2009; 14:774–785
79. Nielsen PR, Benros ME, Mortensen PB. Hospital contacts with infection and risk of schizophrenia: a population-based cohort study with linkage of Danish national registers. Schizophr Bull. 2014; 40:1526–1532
80. Ohtsuki T, Sakurai K, Dou H, Toru M, Yamakawa-Kobayashi K, Arinami T. Mutation analysis of the NMDAR2B (GRIN2B) gene in schizophrenia. Mol Psychiatry. 2001; 6:211–216
81. Perrin MC, Brown AS, Malaspina D. Aberrant epigenetic regulation could explain the relationship of paternal age to schizophrenia. Schizophr Bull. 2007; 33:1270–1273
82. Petersen L, Mortensen PB, Pedersen CB. Paternal age at birth of first child and risk of schizophrenia. Am J Psychiatry. 2011; 168:82–88
83. Plitman E, Iwata Y, Caravaggio F, Nakajima S, Chung JK, Gerretsen P, et al. Kynurenic acid in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2017; 43:764–777
84. Pouget JG, Gonçalves VF, Spain SL, Finucane HK, Raychaudhuri S, Kennedy JL, Knight J; Schizophrenia Working Group of the Psychiatric Genomics Consortium. Genome-wide association studies suggest limited immune gene enrichment in schizophrenia compared to 5 autoimmune diseases. Schizophr Bull. 2016; 42:1176–1184
85. Purcell SM, Wray NR, Stone JL, Visscher PM, O’Donovan MC, Sullivan PF, Sklar P; International Schizophrenia Consortium. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009; 460:748–752
86. Rapoport JL, Giedd JN, Gogtay N. Neurodevelopmental model of schizophrenia: update 2012. Mol Psychiatry. 2012; 17:1228–1238
87. Richards M, Iijima Y, Kondo H, Shizuno T, Hori H, Arima K, et al. Association study of the vesicular monoamine transporter 1 (VMAT1) gene with schizophrenia in a Japanese population. Behav Brain Funct. 2006; 2:39
88. Ripke S, O’Dushlaine C, Chambert K, Moran JL, Kähler AK, Akterin S, et al.; Multicenter Genetic Studies of Schizophrenia Consortium; Psychosis Endophenotypes International Consortium; Wellcome Trust Case Control Consortium 2. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet. 2013; 45:1150–1159
89. Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA, Andreassen OA. Genome-wide association study identifies five new schizophrenia loci. Nature genetics. 2011; 10:43
90. Roman-Blas JA, Jimenez SA. NF-kappab as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage. 2006; 14:839–848
91. Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT. Neurobiology of schizophrenia. Neuron. 2006; 52:139–153
92. Santoro ML, Ota V, de Jong S, Noto C, Spindola LM, Talarico F, et al. Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort. Transl Psychiatry. 2018; 8:174
93. Schizophrenia Psychiatric Genome-Wide Association Study, C. Genome-wide association study identifies five new schizophrenia loci. Nat Genet. 2011; 43:969–976
94. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014; 511:421–427
95. Schwieler L, Larsson MK, Skogh E, Kegel ME, Orhan F, Abdelmoaty S, et al. Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia–significance for activation of the kynurenine pathway. J Psychiatry Neurosci. 2015; 40:126–133
96. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1987; 1:133–152
97. Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, et al.; Schizophrenia Working Group of the Psychiatric Genomics Consortium. Schizophrenia risk from complex variation of complement component 4. Nature. 2016; 530:177–183
98. Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe’er I, et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature. 2009; 460:753–757
99. Shirts BH, Wood J, Yolken RH, Nimgaonkar VL. Association study of IL10, IL1BETA, and IL1RN and schizophrenia using tag SNPs from a comprehensive database: suggestive association with rs16944 at IL1BETA. Schizophr Res. 2006; 88:235–244
100. Smith RG, Reichenberg A, Kember RL, Buxbaum JD, Schalkwyk LC, Fernandes C, Mill J. Advanced paternal age is associated with altered DNA methylation at brain-expressed imprinted loci in inbred mice: implications for neuropsychiatric disease. Mol Psychiatry. 2013; 18:635–636
101. Snow WM, Stoesz BM, Kelly DM, Albensi BC. Roles for NF-κb and gene targets of NF-κb in synaptic plasticity, memory, and navigation. Mol Neurobiol. 2014; 49:757–770
102. Sriretnakumar V, Zai CC, Wasim S, Barsanti-Innes B, Kennedy JL, So J. Copy number variant syndromes are frequent in schizophrenia: progressing towards a CNV-schizophrenia model. Schizophr Res. 2019; 209:171–178
103. St Clair D, Xu M, Wang P, Yu Y, Fang Y, Zhang F, et al. Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959-1961. JAMA. 2005; 294:557–562
104. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, et al.; Genetic Risk and Outcome in Psychosis (GROUP). Common variants conferring risk of schizophrenia. Nature. 2009; 460:744–747
105. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 2002; 71:877–892
106. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. 2003; 60:1187–1192
107. Sun J, Jia P, Fanous AH, van den Oord E, Chen X, Riley BP, et al. Schizophrenia gene networks and pathways and their applications for novel candidate gene selection. Plos One. 2010; 5:e11351
108. Tam GW, Redon R, Carter NP, Grant SG. The role of DNA copy number variation in schizophrenia. Biol Psychiatry. 2009; 66:1005–1012
109. Tan HY, Nicodemus KK, Chen Q, Li Z, Brooke JK, Honea R, et al. Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. J Clin Invest. 2008; 118:2200–2208
110. Torrey EF, Miller J, Rawlings R, Yolken RH. Seasonality of births in schizophrenia and bipolar disorder: a review of the literature. Schizophr Res. 1997; 28:1–38
111. Verdoux H. Perinatal risk factors for schizophrenia: how specific are they?. Curr Psychiatry Rep. 2004; 6:162–167
112. Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science. 2008; 320:539–543
113. Wang W, Corominas R, Lin GN. De novo mutations from whole exome sequencing in neurodevelopmental and psychiatric disorders: from discovery to application. Front Genet. 2019; 10:258
114. Wang Z, Li P, Wu T, Zhu S, Deng L, Cui G. Axon guidance pathway genes are associated with schizophrenia risk. Exp Ther Med. 2018; 16:4519–4526
115. Watanabe Y, Nunokawa A, Kaneko N, Muratake T, Arinami T, Ujike H, et al. Two-stage case-control association study of polymorphisms in rheumatoid arthritis susceptibility genes with schizophrenia. J Hum Genet. 2009; 54:62–65
116. Wei J, Hemmings GP. The NOTCH4 locus is associated with susceptibility to schizophrenia. Nat Genet. 2000; 25:376–377
117. Weickert CS, Straub RE, McClintock BW, Matsumoto M, Hashimoto R, Hyde TM, et al. Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch Gen Psychiatry. 2004; 61:544–555
118. Wong AHC, Van Tol HHM. Schizophrenia: from phenomenology to neurobiology. Neuroscience & Biobehavioral Reviews. 2003; 27:269–306
119. Wright P, Nimgaonkar VL, Donaldson PT, Murray RM. Schizophrenia and HLA: a review. Schizophr Res. 2001; 47:1–12
120. Yang AC, Tsai SJ. New targets for schizophrenia treatment beyond the dopamine hypothesis. Int J Mol Sci. 2017; 18:E1689
121. Yolken RH, Karlsson H, Yee F, Johnston-Wilson NL, Torrey EF. Endogenous retroviruses and schizophrenia. Brain Res Brain Res Rev. 2000; 31:193–199
122. Zhang JP, Robinson D, Yu J, Gallego J, Fleischhacker WW, Kahn RS, et al. Schizophrenia polygenic risk score as a predictor of antipsychotic efficacy in first-episode psychosis. Am J Psychiatry. 2019; 176:21–28

MeSH Term